Current issues in global tuberculosis control
Authors:
- Richard FrothinghamRFRichard Frothingham
- Jason E. StoutJSJason E. Stout
- Carol Dukes HamiltonCHCarol Dukes Hamilton
- 1 November 2005
- journal article
- review article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 9 (6) , 297-311
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases (K23 AI07392)
- National Institute of Allergy and Infectious Diseases (K24 AI001833)
- U.S. Department of Veterans Affairs
- National Institutes of Health
This publication has 71 references indexed in Scilit:
- Hepatotoxicity of Rifampin and Pyrazinamide in the Treatment of Latent Tuberculosis Infection in HIV-Infected Persons: Is It Different Than in HIV-Uninfected Persons?Clinical Infectious Diseases, 2004
- Use of Isoniazid for Latent Tuberculosis Infection in a Public Health ClinicAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Fatal Liver Injury Associated With Rifampin-Pyrazinamide Treatment of Latent Tuberculosis InfectionChest, 2003
- Pyrazinamide and Rifampin vs Isoniazid for the Treatment of Latent TuberculosisChest, 2003
- Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected PersonsAn International Randomized TrialJAMA, 2000
- A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1997
- Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infectionThe Lancet, 1993
- Toxic Hepatitis with Isoniazid and RifampinChest, 1991
- Isoniazid-Associated HepatitisAmerican Review of Respiratory Disease, 1972